Isabelle Van Praagh

Screening for Vulnerability in Older Cancer Patients: The ONCODAGE Prospective Multicenter Cohort Study

Pierre Soubeyran, Carine Bellera, Jean Goyard et al. · PLoS ONE · 2014 · 565 citations · Full text

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 125 citations

Breast Oncology, Oncology, Early Breast Cancer +6

Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

Jean‐Marc Nabholtz, Catherine Abrial, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2014 · 122 citations

Breast Oncology, Medicine, Treatment Impact +8

Clinical and pathological response to primary chemotherapy in operable breast cancer

P. Chollet, Sabine Charrier, Étienne Brain et al. · European Journal of Cancer · 1997 · 121 citations

Surgical Oncology, Breast Oncology, Medicine +8

Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy

S. Amat, Frédérique Penault‐Llorca, H. Curé et al. · International Journal of Oncology · 2002 · 116 citations

Pleiotropic Marker, Surgical Oncology, Breast Oncology +12